Curis, Inc. (NASDAQ:CRIS)’s share price rose 5.8% during mid-day trading on Thursday . The company traded as high as $0.74 and last traded at $0.73. Approximately 1,703,898 shares were traded during mid-day trading, an increase of 109% from the average daily volume of 813,517 shares. The stock had previously closed at $0.69.

CRIS has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on Curis in a report on Monday, October 23rd. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Finally, ValuEngine raised Curis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Curis presently has a consensus rating of “Hold” and a consensus target price of $6.50.

The stock has a market capitalization of $121.61, a price-to-earnings ratio of -1.87 and a beta of 1.62. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The business had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.19 million. During the same period in the prior year, the business earned ($0.21) earnings per share. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. sell-side analysts predict that Curis, Inc. will post -0.41 EPS for the current fiscal year.

In other Curis news, CEO Ali Ph.D. Fattaey purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of $1.06 per share, with a total value of $53,000.00. Following the acquisition, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at approximately $122,843.40. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.07% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Curis by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after buying an additional 127,443 shares during the last quarter. State Street Corp boosted its position in Curis by 10.4% in the 2nd quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after buying an additional 175,424 shares during the last quarter. First Eagle Investment Management LLC boosted its position in Curis by 10.4% in the 3rd quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after buying an additional 2,500,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Curis by 1.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 1,880 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Curis by 58.7% in the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 13,448 shares during the last quarter. Hedge funds and other institutional investors own 55.22% of the company’s stock.

WARNING: This piece was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://theolympiareport.com/2017/12/28/curis-cris-shares-up-5-8.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with Analyst Ratings Network's FREE daily email newsletter.